|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||5.56 - 5.95|
|52-week range||5.56 - 5.95|
|Beta (5Y monthly)||0.99|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.
The European Commission in July slashed its order for VLA2001 to just 1.25 million doses from a previously targeted 60 million, pointing to European countries being well supplied with other vaccines and a slowdown in vaccination programmes. In February, Valneva had said it expected 350-500 million euros in COVID-19 vaccine sales. In the six months to June, the shot's sales brought in 3.8 million euros and the firm recognised writedowns of 100.6 million linked to the production inventory it bought to meet the initial purchase agreement with the European Commission, and subsequent halt of production.
As the first company to introduce a COVID-19 vaccine, pharmaceutical behemoth Pfizer (NYSE: PFE) experienced enormous windfalls by delivering primary and booster shots on a global scale. Now, Pfizer is developing a vaccine for another infectious disease with a wide-open market. Pfizer will invest about $95 million in specialty vaccine maker Valneva, based in France.